Irradiation after Surgery for Breast Cancer Patients with Primary Tumours and One to Three Positive Axillary Lymph Nodes: Yes or No?

Author:

Lu C.,Xu H.,Chen X.,Tong Z.,Liu X.,Jia Y.

Abstract

Objective and Methods: We retrospectively analyzed clinicopathologic features and survival in breast cancer patients who had T1 or T2 primary tumours and 1–3 histologically involved axillary lymph nodes and who were treated with modified radical mastectomy without adjuvant radiotherapy (RT). We also explored prognosis to find the high- and low-risk groups. Results: From May 2001 to April 2005, 368 patients treated at Tianjin Tumor Hospital met the study criteria. The 5- and 8-year rates were 7.2% and 10.7% for locoregional recurrence (LRR), 85.1% and 77.7% for disease-free survival (DFS), and 92.8% and 89.3% for overall survival (OS). Multivariate Cox regression analysis showed that age, tumour size, estrogen receptor (ER) status, and lymphovascular invasion (LVI) were independent prognostic factors for LRR and DFS. Based on 4 patient-related factors that indicate poor prognosis (age < 40 years, tumour > 3 cm, ER negativity, and LVI), the high-risk group (patients with 3 or 4 factors, accounting for 12.5% of the cohort) had 5- and 8-year rates of 24.3% and 36.9% for LRR, 57.2% and 39.2% for DFS, and 74.8% and 43.8% for OS compared with 5.0% and 7.1% for LRR, 88.9% and 83.1% for DFS, 91.6% and 83.4% for OS in the low-risk group (patients with 0–2 factors, accounting for 87.5% of the cohort; p < 0.001). Conclusions: Our study identified several risk factors that correlated independently with a greater incidence of LRR and distant metastasis in patients with T1 and T2 breast cancer and 1–3 positive nodes. Patients with 0–2 risk factors may not be likely to benefit from post-mastectomy RT, but patients with 3–4 risk factors may need RT to optimize locoregional control and improve survival.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3